Lukas Biomedical

Lukas Biomedical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is 81.68 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 81.96 % — a change of -0.33% (lower).

FCF Conversion

81.68 %

YoY

-0.33%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lukas Biomedical is 2025 81.68 % . FCF Conversion Rate (FCF/EBITDA) of Lukas Biomedical was 2024 81.96 % . It decreases by -0.33% lower compared to the previous year.

The Lukas Biomedical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
24.06 TWD
Jan 1, 2019
68.87 TWD
Jan 1, 2020
-190.14 TWD
Jan 1, 2021
52.90 TWD
Jan 1, 2022
20.79 TWD
Jan 1, 2023
30.42 TWD
Jan 1, 2024
81.96 TWD
Jan 1, 2025
81.68 TWD
The Lukas Biomedical FCF Conversion history
YEARFCF ConversionYoY
81.68 %-0.33%
81.96 %+169.38%
30.42 %+46.31%
20.79 %-60.69%
52.90 %-127.82%
-190.14 %-376.11%
68.87 %+186.24%
24.06 %-91.19%
273.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

FCF Conversion Rate (FCF/EBITDA) of Lukas Biomedical is 81.68 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Lukas Biomedical changed from 81.96 % to 81.68 %, representing a -0.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lukas Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lukas Biomedical

All Key Metrics — Lukas Biomedical